Format

Send to

Choose Destination
See comment in PubMed Commons below
MAGMA. 2001 May;12(2-3):128-34.

Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent.

Author information

  • 1Schering AG, Diagnostic Imaging Division, Contrast Media Research, Müllerstr. 178, D-13342 Berlin, Germany. bernd.misselwitz@schering.de

Abstract

RATIONALE AND OBJECTIVES:

Gadomer-17 is a new magnetic resonance (MR) contrast medium presently in clinical development. It is a dendritic gadolinium (Gd) chelate carrying 24 Gd ions. This study investigated the pharmacokinetic behavior of this contrast medium.

METHODS:

The pharmacokinetics of Gadomer-17 were investigated in different species (rat, rabbit, dog, monkey) for up to 7 days after intravenous (i.v.) injection of 25-100 micromol/kg body weight. In addition, elimination and biodistribution were evaluated after single i.v. injection of Gadomer-17 in rats.

RESULTS:

After i.v. injection Gadomer-17 distributes almost exclusively within the intravascular space without significant diffusion into the interstitial space. The volume of distribution (Vc) in the initial or alpha-phase ranged from 0.04 l/kg (rats, rabbits) to 0.06 l/kg (monkeys) and 0.07 l/kg (dogs), which reflects mainly the plasma volume. The blood/plasma concentration profile was found to be biphasic. The volume of distribution at a steady state is clearly smaller than that of other contrast media, which distribute to the extracellular space. After single i.v. injection in rats, the dendritic contrast medium was rapidly and completely eliminated from the body, mainly via glomerular filtration. No long-term accumulation or retention of the nonmetabolized agent was detectable in organs or tissues.

CONCLUSIONS:

Gadomer-17 is a promising new MR contrast medium that has an intravascular distribution and a rapid renal elimination.

PMID:
11390268
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk